Premium
Anticoagulation and Monitoring of a Novel and Reversible Factor IXa Inhibitor
Author(s) -
Becker Richard C.,
Chan Mark Y.,
Vavalle John P.,
Povsic Thomas J.
Publication year - 2013
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.21109
Subject(s) - thrombosis , medicine , proteases , factor ixa , immunology , factor x , platelet , chemistry , thrombin , biochemistry , enzyme
Clinical Development Phases I‐III Regulatory, Quality, ManufacturingThrombosis as a clinical phenotype is ubiquitous in human diseases and conditions, ranging from atherosclerosis and other vascular disorders to trauma, surgery, malignancy, infections, blood dyscrasias, auto‐immunity, and complications of pregnancy. While each condition carries its own distinct signature and predisposition for thrombosis as a nonphysiological event, there are several common themes that center on cellular and noncellular elements, including well‐characterized coagulation proteases. Over the past decade, our group has been actively involved with the development of a factor IXa inhibitor, pegnivacogin, and its complementary antidote or control agent, anivamersen. The following review provides a summary of fundamental constructs, milestones, and the current status of our translational journey.